---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-22-000022"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-23T00:35:41.247116+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gilead Q3 revenue $7.0B, EPS $1.42; raises full-year guidance

## Summary
- Total revenue $7.0B (-5% YoY); core product sales ex-Veklury up 11% to $6.1B.
- GAAP diluted EPS $1.42 (vs $2.05); Non-GAAP EPS $1.90 (vs $2.65).
- Biktarvy sales +22% to $2.8B; oncology sales +79% to $578M; Veklury -52% to $925M.
- Raises 2022 guidance: product sales $25.9-$26.2B, Non-GAAP EPS $6.95-$7.15.
- Acquired IPR&D $448M, including $389M for MiroBio; operating CF $2.9B in Q3.

## SEC filing metadata
- accession: 0000882095-22-000022
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209522000022/0000882095-22-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209522000022/gild-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-22-000022
- JSON: https://secwatch.observer/filing/0000882095-22-000022.json
- Plain text: https://secwatch.observer/filing/0000882095-22-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.